After filing plans for an initial public offering earlier in April, U.K.-based Vaccitech raised $110.5 million in the company’s IPO and on April 30 announced the pricing of 6.5 million American Depositary Shares at $17 per share. 

The U.S. government on Feb. 27 authorized Johnson & Johnson’s single-dose Covid-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting the vaccine up for additional approvals around the world.

Gilead Sciences inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.

Scientists from across the globe expressed concern over the lack of available data that could provide a key to how well the world’s first Covid-19 vaccine – approved in Russia without going through Phase III testing – could work stemming the rise of the novel coronavirus.